Capital Advisors Wealth Management LLC Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY)

Capital Advisors Wealth Management LLC trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 26.7% in the second quarter, Holdings Channel reports. The firm owned 3,219 shares of the biopharmaceutical company’s stock after selling 1,174 shares during the period. Capital Advisors Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $206,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Cigna Investments Inc. New increased its stake in Bristol-Myers Squibb by 0.5% in the 4th quarter. Cigna Investments Inc. New now owns 26,379 shares of the biopharmaceutical company’s stock valued at $1,898,000 after buying an additional 141 shares during the last quarter. Catalyst Financial Partners LLC increased its holdings in Bristol-Myers Squibb by 2.5% during the first quarter. Catalyst Financial Partners LLC now owns 6,001 shares of the biopharmaceutical company’s stock worth $416,000 after buying an additional 145 shares during the last quarter. Keystone Wealth Services LLC boosted its stake in Bristol-Myers Squibb by 2.0% in the first quarter. Keystone Wealth Services LLC now owns 7,468 shares of the biopharmaceutical company’s stock valued at $518,000 after acquiring an additional 148 shares during the last quarter. Dillon & Associates Inc. raised its holdings in shares of Bristol-Myers Squibb by 3.9% in the 1st quarter. Dillon & Associates Inc. now owns 3,955 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 150 shares during the period. Finally, Abbrea Capital LLC grew its holdings in Bristol-Myers Squibb by 1.5% during the first quarter. Abbrea Capital LLC now owns 10,025 shares of the biopharmaceutical company’s stock valued at $695,000 after purchasing an additional 150 shares during the period. Institutional investors and hedge funds own 74.98% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Robert M. Plenge sold 732 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total transaction of $44,754.48. Following the completion of the transaction, the executive vice president now directly owns 6,584 shares in the company, valued at $402,545.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Robert M. Plenge sold 732 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total transaction of $44,754.48. Following the sale, the executive vice president now owns 6,584 shares in the company, valued at $402,545.76. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the completion of the transaction, the executive vice president now owns 27,868 shares of the company’s stock, valued at $1,706,915. The disclosure for this sale can be found here. Corporate insiders own 0.08% of the company’s stock.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $58.58 on Tuesday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.39 and a quick ratio of 1.28. Bristol-Myers Squibb has a 1 year low of $58.33 and a 1 year high of $81.43. The company’s 50-day moving average is $61.62 and its 200 day moving average is $65.11. The stock has a market capitalization of $122.38 billion, a P/E ratio of 15.58, a P/E/G ratio of 1.57 and a beta of 0.42.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, missing the consensus estimate of $1.99 by ($0.24). The firm had revenue of $11.23 billion during the quarter, compared to analysts’ expectations of $11.81 billion. Bristol-Myers Squibb had a return on equity of 50.51% and a net margin of 17.62%. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.93 earnings per share. On average, sell-side analysts expect that Bristol-Myers Squibb will post 7.44 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on BMY shares. Wells Fargo & Company cut their price target on Bristol-Myers Squibb from $78.00 to $65.00 and set an “equal weight” rating for the company in a research note on Friday, July 28th. Credit Suisse Group cut their price objective on shares of Bristol-Myers Squibb from $72.00 to $66.00 in a report on Wednesday, July 12th. HSBC assumed coverage on shares of Bristol-Myers Squibb in a report on Friday, July 14th. They set a “reduce” rating and a $56.00 target price on the stock. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 1st. Finally, SVB Leerink reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, July 10th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $70.67.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.